{"name":"SetPoint Medical Corporation","slug":"setpoint-medical-corporation","ticker":"","exchange":"","domain":"setpointmedicalcorporation.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Conventional Synthetic DMARD","genericName":"Conventional Synthetic DMARD","slug":"conventional-synthetic-dmard","indication":"Rheumatoid arthritis","status":"phase_3"}]}],"pipeline":[{"name":"Conventional Synthetic DMARD","genericName":"Conventional Synthetic DMARD","slug":"conventional-synthetic-dmard","phase":"phase_3","mechanism":"Conventional synthetic DMARDs suppress immune system activity through inhibition of inflammatory pathways to reduce joint inflammation and slow disease progression in rheumatoid arthritis.","indications":["Rheumatoid arthritis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOZDBaS2g3LXAwNmE0TTBoMFR2eHY0WjhybGFlZGdENDc5YlBCSGdCVzU0LVlldG5CSjZldE9QaUVaLW5zcVFyTi14Y0NZYXhSVmZzQnVxT3lvbzd6alB4TllyMG9rUUlPalFKbEltMXJUYWw4ZThwSWMxTy1tNjhmcHlMUTlvQUpmV2QydVhwcms5OFBta2w5elFmRkY2dEpKUkM1eEQ1TWR1YlV3cVZnNzhBZVJjMjBCYUVrQ0RxZkpfSmV1TXU4cU9RVTVIWVZkMUxKSzlUcjlHU0RIZGtwWVo4ZWMtbjlWMHFiYUdOSGRlN2VCREttTkVQXy1XdEhMMFJRdUlsQkJUekhYQzB5MjlySWVRc2JmdDFETVpRVzM5amowTkE?oc=5","date":"2026-03-11","type":"pipeline","source":"PR Newswire","summary":"SetPoint Medical Announces First SetPoint® System Procedure in Texas, Performed at Ascension Dell Seton Medical Center at The University of Texas - PR Newswire","headline":"SetPoint Medical Announces First SetPoint® System Procedure in Texas, Performed at Ascension Dell Seton Medical Center a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxNdHlrMGk3cUpOQVdncUxTaTRDZnZpdWNLaDBOd2hWNmxMWHp5X1Bjc01fSmRueUc5NjIxUFFVVnBabVE0Wm1uY1JCcWxFWHlvbk1MM1ZRT1kweTQ4RHdia1J1bG4xVDBpZ2lRYXJydXdvS0NqNUFXc2xoUjJDUFdFNGhLOXpsUGNZaHhSY1l3ZnAxQ1JhZDl5WTZuemx0WUJBQzJwM3hXRUt6MzVYU3l2YXR5c3c4dmstSmhNZnkxaDhGZWpUenJyNVFtZE5hWEJpdHhDSHlfUnp3T3VMemthMV9palFuQmtmNFlDR2xRNldaRlhWeUNkeGk5UVI5eEt1WEo2dlJYcHJ4TVhMa2VDMWFaTmR6NmZmRjFsRzIyRjg2b1RPQlNXOVBPSGVGTFNlNl9SblloaThwcnFTanp5UFA5X3JDN3FCWURaSks5N21iUQ?oc=5","date":"2026-01-23","type":"regulatory","source":"Barchart.com","summary":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Eli Lilly and Company, Philogen, I-Mab Biopharma, Teijin Pharma, Revolo - ","headline":"Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxOcVZ4VUNiOWNzbmxub1VaZGhjQVRhUHEwazhidnFmcGtDNDd0d1NzX3ZWOUFoaTl4NFJmTVEtNjJUaGp5a2stbzFYbzNRcEttZDRmOHBFelZ5RUNDajg1cnh2clpySDhfdzBuSHQwVkpZRk9qVGFydTFqa182bUVWXzBOUTVnVU9ZUEF3WHhLSzVZZy1zdlctOXFEYlZSaFN1S3lUTVBRNjJubTVTNVpKNEdPMW5aLXMxeWdhNVdmUTVHckI2ZVZIdHE1Z3JnbkNrSlBMaXlNRUtXTzBWRFFxdkd1c19rQ05jLXhr?oc=5","date":"2026-01-22","type":"pipeline","source":"Business Wire","summary":"United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors - Business Wire","headline":"United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxOaHRYdGFXU1VoWjNJNmFBcko1OGU3a2lqRjdKajNPVHFiT0FydVR4cEQtaTB3M1FDZVBUaFlsSlVnOVlWTzlKSkVkaTlRS2M4a0RIUUg4ekZFOXpCbTBrVzB4a0xiVnVvVzVfdWhaTS0wV0g2aGVRVkhOWkh2LWlXN3NVSjVOcGhCbEdWQVFveDdsNkpuR2tJeDlFcUdGQzItZVpKejA2dHdyTnhxWEdrQXNQLWJCTENnWXBoSUhTNnBKRHdfT1VSOF81Q1lZeVhjZC1QWldXeDNIN3NkWmlJQ0ZqSU9tSUptdjJhT0NFVWV5dGV3dWNIY0hEMXVKYnpvaUZiblQyRFAxcG9yVFE?oc=5","date":"2026-01-05","type":"trial","source":"BioSpace","summary":"Landmark RESET-RA Study Published in Nature Medicine Demonstrates Durable Efficacy and Safety of the SetPoint System for Rheumatoid Arthritis - BioSpace","headline":"Landmark RESET-RA Study Published in Nature Medicine Demonstrates Durable Efficacy and Safety of the SetPoint System for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOeW12R3lhb2FjQXFYQ2Z4RVNnRUxiR1dMbUhJd0ZXMW1rOHhZS0NxMFgtTFV0ZGxCbmFZTkc0VWpsYUZQNUtCNllfV1NjTmRzanI0dDhIdWxVNHI1TGxBeU45NXItOGF5SGFocnB3TXFXYlRqSjFyTWE2bndLVkJGMG1haXNXNVcxUS1vVURxdXU1Mm5xV3l2b2NEY3g?oc=5","date":"2025-12-15","type":"pipeline","source":"globalventuring.com","summary":"UK pharma group GSK spins out corporate VC arm - globalventuring.com","headline":"UK pharma group GSK spins out corporate VC arm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPZHh2dlRWbVVpWnRDV1RyTzJFX0ZEY1ViRWUyaVdvVTl5WUdGMFppN3o3cXJxME4yMmhXSzlTaEkxSm1xUnByalo4WDRrcElRQWxESzZCZjhneHNIUzdEa2Y2WVdETFFuVU1WLUw1dHZLWUwwNW50Q1dodHcxbDV0djdYNnZUOC1VWTBRWC1LX1pNOXNjVzQ2eVFMRGV0TUFmclp5Qk14d2tlSVpVTEcwNjNxalBhMThLU1VCM3E4WDFIUQ?oc=5","date":"2025-11-14","type":"regulatory","source":"Healio","summary":"Approval of vagus nerve stimulator may herald ‘pivot point’ for rheumatology - Healio","headline":"Approval of vagus nerve stimulator may herald ‘pivot point’ for rheumatology","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPMUNlaWJsYm9lNzNTaHM4SmtabUlxUW9ZelFiM2NVRFA4eE9iSXBic2dvRHNrZzd0X0ZMT3JtZC1nTUJXOC1RZEVxbUJsVXRnblByTlJWdm5wbXVzVkVyNkJ6OGJiVDhwM1FXTWR1Vl9acm5GeGNldVRoWUpsdGg3ZmgydGYwZzRydERHYnAwNzF6OXZEWS1vT1dZYUljVEZmYmtWc05qeXdhRmdSTWRLbmRBQ2xWYzBvejREQzlRdnFzVHVwckVhTFR2dERPOHN6empWSUx1eGZZTXNrQ3JFN00wMTF5REsxN0RYY0k5S0RIN0lyZWxIXzBiV3JBNUVBNGZJZWkyeGxnRE5tOGtRdlE3OUpXNWsxMjhEejA3SQ?oc=5","date":"2025-10-27","type":"trial","source":"BioSpace","summary":"SetPoint Medical to Present Data at ACR Convergence 2025 Demonstrating Sustained Efficacy and Safety for the SetPoint System to Treat Rheumatoid Arthritis - BioSpace","headline":"SetPoint Medical to Present Data at ACR Convergence 2025 Demonstrating Sustained Efficacy and Safety for the SetPoint Sy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNX2d3OUtsODVkWWVtbE15RE12VGpIbHljNlI5em5NS0pPRFlmdlZlcXhTUUVQejVLUTlXSm0tZFk0SENfVWFPZUNQTm05ZWhHa2xPd0V6UzFNMmxiRG9nTldmSm1CWEhHZkR5M0NFNUhjYmhvQmtjV3JNZ1VOMEhZbw?oc=5","date":"2025-08-26","type":"pipeline","source":"valley.labusinessjournal.com","summary":"SetPoint Medical Hits Market - valley.labusinessjournal.com","headline":"SetPoint Medical Hits Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPN1h0SDdtUTRWdTJKcXcybHhjODVWeE9zd2JWUjdVM3FoSGo5TXZvUlFfeURwQVVtZDlnQnNyRjdTYjdmMWhObHZvUEw1bWRROExqeU95TG5sM0NIWUs5dkl4d09hYXdseU9lWVEyTXV4dlpVdk9RbGNSYml0djI3ckRFX2JFQjZrWFB3Wg?oc=5","date":"2025-08-26","type":"pipeline","source":"MassDevice","summary":"SetPoint reports first commercial use of neuromod for arthritis - MassDevice","headline":"SetPoint reports first commercial use of neuromod for arthritis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNNlk5ZXBEMVBCNk5MOVBpcWtYcDJibll3eGRKZHFFa0JEWkR4U28tUDl1Z2FiX05SaDR2Nl81RW5SVUlMS01kS2ZudFJkbHRWb1RXNTJXZGNzM2JYVi0zc2E1M2VETC1nRXhpUkVZdmRZcWh3MEZRd05tVmlUOExUOUdWZVM4UWxqaUp1QmxIQmEzaXJXdVZrOUw0QmpCR1A0Z0tKUWktNVNlcElFQXZiTjB2VWxzVUk2WmNaSE9Vaw?oc=5","date":"2025-08-11","type":"regulatory","source":"Fierce Biotech","summary":"SetPoint serves up $140M fundraising after FDA approves its implant for rheumatoid arthritis - Fierce Biotech","headline":"SetPoint serves up $140M fundraising after FDA approves its implant for rheumatoid arthritis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOZGY2UmNIVXJaT1VZQl9KMnlGUEtub3hEVXFUU0NDTDBTaFdvQTVUcm5RTTZLLWJ2Y2hnNnRhVGhrdzRkQkZFQ1RuM3RpT3B2dDV0c2MxNTlaWVp3YzNhbzZScDRuSFRJWElIcUNmajhQZklLR1lrMmZHejhGMGUwQmtScmdOVjlMcURDYmtERVFSRWw3TnU5VndqYVRCR3pDaVA4QVJB?oc=5","date":"2025-08-11","type":"regulatory","source":"BioWorld News","summary":"Setpoint sports back-to-back wins with FDA approval, $140M raise - BioWorld News","headline":"Setpoint sports back-to-back wins with FDA approval, $140M raise","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOYzVZbTNkekJnWlc2VEk5cEZET2ZCYTU4YkFxRFAyc0FGUmtlM2pMV3VVVWJuaUVEd3E2dU1uczhJckhWZWsyTldpTzY1NGQ5em9NWEtrWU8wc2R4WE5FZ1JTaTBqbFBIRV9NcmJEVTd1M3FIczZfazZYRW1XZFRydFd6ZzJOcWVabjhPVFJDbjExNFFWRXlDemtPRl94WkFTUkxTUXdMQVAwcy1LV2NMT1Y5RWNsS2tNdzNHOXFBWG1MQ213b0VRbkpuUjVqVS1WSTNqblYzTnlYUjByb1E?oc=5","date":"2025-08-08","type":"pipeline","source":"Smithsonian Magazine","summary":"New, Implanted Device Could Offer a Long-Elusive, Drug-Free Treatment for Rheumatoid Arthritis - Smithsonian Magazine","headline":"New, Implanted Device Could Offer a Long-Elusive, Drug-Free Treatment for Rheumatoid Arthritis","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}